Viking Therapeutics, based in San Diego, develops therapies for metabolic and endocrine disorders, including VK2809 for NASH, VK0214 for X-ALD, and VK2735 for metabolic issues. The company went public on April 29, 2015, and has 28 employees.
Greg Zante sold 50,309 shares of VKTX on 6 January at $43.32 per share, worth a total of $2.2M. They now own 169,959 VKTX shares, or a 23% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
